Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy
Source abstract
Abstract
Inducing death receptor 5 (DR5) clustering holds particular promise in tumor-specific therapeutics because it could trigger an apoptotic cascade in cancerous cells. Herein, we present a tumor microenvironment H 2 O 2 -responsive self-illuminating nanoagonist, which could induce dual tumor cell death pathways through enhancing DR5 clustering. By conjugating DR5 ligand peptides onto the surfaces of self-illuminating nanoparticles with cross-linking capacity, this strategy not only provides scaffolds for ligands to bind receptors but also cross-links them through photo-cross-linking. This strategy allows for efficient activation of DR5 downstream signaling, initiating the extrinsic apoptosis pathway and immunogenic cell death of tumor cells, and contributes to improved tumor-specific immune responses, resulting in enhanced antitumor efficacy and minimized systemic adverse effects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, P. R. China
Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, 289 Kuocang Road, Lishui 323000, P. R. China
Department of Hematology, the Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, Hangzhou 310006, P. R. China
Innovation Center of Transformational Pharmacy, Jinhua Institute of Zhejiang University, Jinhua 321299, P. R. China
Funding
National Key Research and Development Program of China · Natural Science Foundation of Zhejiang Province
References (49)
Show source-provided references
1. 10.1007/s10555-018-9728-y10.1007/s10555-018-9728-y ↗
2. 10.1038/s41422-022-00772-110.1038/s41422-022-00772-1 ↗
3. 10.1007/s12272-018-01103-y10.1007/s12272-018-01103-y ↗
4. 10.1016/0092-8674(93)90464-210.1016/0092-8674(93)90464-2 ↗
5. 10.1038/nrc.2017.2810.1038/nrc.2017.28 ↗
6. 10.1038/cddis.2016.17710.1038/cddis.2016.177 ↗
7. 10.1158/1078-0432.CCR-05-015810.1158/1078-0432.CCR-05-0158 ↗
8. 10.1158/1078-0432.CCR-11-009910.1158/1078-0432.CCR-11-0099 ↗
9. 10.1038/s41388-021-02041-810.1038/s41388-021-02041-8 ↗
10. 10.1158/0008-5472.CAN-21-306210.1158/0008-5472.CAN-21-3062 ↗
11. 10.1016/j.ccr.2014.04.02810.1016/j.ccr.2014.04.028 ↗
12. 10.1016/S2352-3026(15)00026-510.1016/S2352-3026(15)00026-5 ↗
13. 10.3978/j.issn.2218-6751.2012.02.0310.3978/j.issn.2218-6751.2012.02.03 ↗
14. 10.1242/jcs.14634010.1242/jcs.146340 ↗
15. 10.1242/jcs.22642310.1242/jcs.226423 ↗
16. 10.1016/0092-8674(95)90404-210.1016/0092-8674(95)90404-2 ↗
17. 10.1016/j.cell.2019.02.00110.1016/j.cell.2019.02.001 ↗
18. 10.1038/nature0760610.1038/nature07606 ↗
19. 10.1158/1535-7163.MCT-15-064710.1158/1535-7163.MCT-15-0647 ↗
20. 10.1158/0008-5472.CAN-20-217810.1158/0008-5472.CAN-20-2178 ↗
21. 10.1073/pnas.141896211210.1073/pnas.1418962112 ↗
22. 10.1158/0008-5472.CAN-09-288910.1158/0008-5472.CAN-09-2889 ↗
23. 10.1002/smll.20220616010.1002/smll.202206160 ↗
24. 10.1002/adma.20140449810.1002/adma.201404498 ↗
25. 10.1158/0008-5472.CAN-09-288910.1158/0008-5472.CAN-09-2889 ↗
26. 10.1126/science.abb765710.1126/science.abb7657 ↗
27. 10.1016/j.sbi.2019.03.02810.1016/j.sbi.2019.03.028 ↗
28. 10.1038/nchembio.153410.1038/nchembio.1534 ↗
29. 10.1002/adhm.20180095410.1002/adhm.201800954 ↗
30. Szatrowski T. P. · Cancer Res. · 1991 · 51 · 794
31. 10.1002/adfm.20200574710.1002/adfm.202005747 ↗
32. 10.1016/j.pharmthera.2020.10775310.1016/j.pharmthera.2020.107753 ↗
33. 10.1002/adma.20180222810.1002/adma.201802228 ↗
34. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
35. 10.1021/nn301490510.1021/nn3014905 ↗
36. 10.1038/nmat198310.1038/nmat1983 ↗
37. 10.1002/adfm.20120077310.1002/adfm.201200773 ↗
38. 10.1002/chem.20120241510.1002/chem.201202415 ↗
39. 10.1002/anie.20151189410.1002/anie.201511894 ↗
40. 10.1016/S1074-7613(00)80211-310.1016/S1074-7613(00)80211-3 ↗
41. 10.1016/S1074-7613(00)80212-510.1016/S1074-7613(00)80212-5 ↗
42. 10.1038/nrd263710.1038/nrd2637 ↗
43. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
44. 10.1038/s41392-019-0104-310.1038/s41392-019-0104-3 ↗
45. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
46. 10.1038/s41586-020-2611-310.1038/s41586-020-2611-3 ↗
47. 10.1084/jem.2012110310.1084/jem.20121103 ↗
48. 10.1016/j.cell.2018.01.00410.1016/j.cell.2018.01.004 ↗
49. 10.1038/s41577-018-0044-010.1038/s41577-018-0044-0 ↗